In an EMS study, only 46% of participants recognized epinephrine as the drug of first choice for anaphylaxis. Only 36% recognized intramuscular (IM) epinephrine as the optimal route.

The new Epi device is called Auvi-Q in the U.S. (https://www.auvi-q.com). Will be called Allerject in Canada and released in early 2013. Who likes the U.S. name?

Allerject device may have a slightly shorter needle length in the pediatric dose (0.15 mg).

Allerject has a 5 second countdown (spoken aloud) once needle activated to inform user how long the device needs to be in place. Allerject needle is retractable after injection and tells you if dose is successful.

This post concludes the Twitter summaries from the 2012 meeting of the Canadian Society of Allergy and Clinical Immunology (CSACI). They were made possible by the hard work and the updates of @allergydoc4kidz @DrAnneEllis @IgECPD4.

Subscribe and Connect

About Us

Disclaimer: All opinions expressed here are those of their authors and not of their employer. The information provided here is for educational purposes only and is not intended to provide medical advice. By accessing the web site, the visitors acknowledge that there is no physician-patient relationship between them and the authors.